Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.
about
Understanding the interplay between host immunity and Epstein-Barr virus in NPC patientsEmerging treatment options for nasopharyngeal carcinomaDiagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia.Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinomaComparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy.Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma?Current management strategy of nasopharyngeal carcinoma.Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignanciesHuman papillomavirus 16 detected in nasopharyngeal carcinomas in white Americans but not in endemic Southern Chinese patientsCirculating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanomaRole of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a Western population.Commutability of the Epstein-Barr virus WHO international standard across two quantitative PCR methods.Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma.Epstein-Barr Virus_Encoded LMP1 upregulates microRNA-21 to promote the resistance of nasopharyngeal carcinoma cells to cisplatin-induced Apoptosis by suppressing PDCD4 and Fas-L.Impact of plasma Epstein-Barr virus-DNA and tumor volume on prognosis of locally advanced nasopharyngeal carcinomaPosttransplant lymphoproliferative disease: pathogenesis, monitoring, and therapy.Elevated high-sensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy eraPhase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group.Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patientsThe impact of plasma Epstein-Barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational studyRole of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research programThe clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 casesPrognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy.Pretreatment Serum Lactate Dehydrogenase and N Classification Predict Long-Term Survival and Distant Metastasis in Patients With Nasopharyngeal Carcinoma Who Have A Positive Family History of Cancer.Positivity of both plasma Epstein-Barr virus DNA and serum Epstein-Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma.Frequency of Epstein Barr Virus Type 1 Among Nasopharyngeal Carcinomas in Iranian PatientsLevels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinomaCurrent and emerging treatment options for nasopharyngeal carcinoma.The role of human papillomavirus in squamous carcinoma of the head and neck.Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngealPrognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers.Validation of a new prognostic index score for disseminated nasopharyngeal carcinomaPrognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation TherapyPrognostic score models for survival of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy and chemotherapy.Fluorodeoxyglucose-positron emission tomography in carcinoma nasopharynx: Can we predict outcomes and tailor therapy based on postradiotherapy fluorodeoxyglucose-positron emission tomography?An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma.
P2860
Q26823898-CF28B946-3697-4C6D-9A13-BFEB04A32879Q26995560-289B744B-36DB-4873-9DC9-ECF3C64A8455Q33218405-4BBAF692-4653-42C2-AB6F-8EFEB7BBEB95Q33262273-E8D8D7E1-14B3-4268-BED1-72330B5BEB3CQ33685029-AD136D4D-1F2A-4C60-8578-43DFF159789DQ33702316-420CAF86-6AD3-4104-A6E1-E5A7245A53FBQ33764579-4DC7A0B1-7D38-4BD2-8A0D-119C3E60C183Q33836183-12032718-1063-45F6-A702-05D05370698EQ33901342-5F458CCF-1CC5-4952-9A43-87F00AD5C71DQ34121782-9DED5E46-23EC-469E-9357-036EE20966E0Q34286259-D35DE934-BAA4-47EE-BB71-D04A99EA2606Q34298224-1DC5D79B-7204-4259-8C90-FBEB1AC5C708Q34565533-817A74CC-1F84-47B5-9315-CCE889412FC2Q35032548-61AA87A2-07DE-45BA-9EA6-92E611678870Q35087399-8401DCE6-0FB0-4E77-8D53-D0910664AD46Q35190684-481C87EB-E474-4327-875E-4FE53ADF72AEQ35391282-932AAD0C-D94C-429A-8589-C0EC3DAD997AQ35507358-11FBA5D1-77AF-48EE-A48B-9548B41FED48Q35619542-5C2612DF-7DAE-4F37-924B-7EC9557A021FQ35670356-6CAD387C-A01C-4243-B302-CF3D1F9B4C7AQ35678382-321E019A-DC03-418D-9D3F-268081BF385AQ35769567-2BD1E7C3-6FED-4B9B-B711-97A8C70F1284Q36076485-7FACBF46-5111-448D-9137-92BDEA0F2ED3Q36117881-B1E45EDF-CE73-4E8B-9BE5-CBEF2188D077Q36152889-3E3761A6-4B83-4D0F-AF06-23B1861CCBABQ36189973-BE099DDC-7308-4EE4-8910-D0B60DE514EDQ36256111-24207013-E90C-46F2-AD71-06C8006760F4Q36305182-3D9B00AD-8E61-43AB-8315-4BD58872E089Q36323473-1FD081CB-EB0C-4222-8554-52C94985FA6EQ36335515-0E35DBE0-E1C8-4F27-8EB6-95F1E17B4799Q36359374-026278BD-A6F8-46C7-92C3-5799C993E19DQ36409233-E2B88D05-7ABF-415A-B654-CB2F5AE85DB7Q36546040-5C25DC89-FC0A-416E-B3FB-76CAD83C2660Q36566873-626FAA58-233D-42B2-B14C-A34C81ABD771Q36610034-EB34D040-C436-4B6B-917F-2B8AA7562FF8Q36616746-3E4A003D-4044-42A1-9B90-A6AD142AAD9CQ36628563-84BF1CD1-68C9-49F2-84C4-5D742300084AQ36629614-1C38BF28-AE19-412B-BE75-8A442999F5C6Q36696385-9B90E5FD-D61E-4A24-B008-C5F2F37678FEQ36778016-5AA66CEF-558E-497B-AEA2-9A16169AAB77
P2860
Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Plasma Epstein-Barr virus DNA ...... ated nasopharyngeal carcinoma.
@en
Plasma Epstein-Barr virus DNA ...... ated nasopharyngeal carcinoma.
@nl
type
label
Plasma Epstein-Barr virus DNA ...... ated nasopharyngeal carcinoma.
@en
Plasma Epstein-Barr virus DNA ...... ated nasopharyngeal carcinoma.
@nl
prefLabel
Plasma Epstein-Barr virus DNA ...... ated nasopharyngeal carcinoma.
@en
Plasma Epstein-Barr virus DNA ...... ated nasopharyngeal carcinoma.
@nl
P2093
P356
P1476
Plasma Epstein-Barr virus DNA ...... ated nasopharyngeal carcinoma.
@en
P2093
Anthony T C Chan
Brigette B Y Ma
Dolly P Huang
Frankie Mo
Lisa Y S Chan
Philip J Johnson
Sing-Fai Leung
Stephen Ho
Y M Dennis Lo
P304
P356
10.1093/JNCI/94.21.1614
P407
P577
2002-11-01T00:00:00Z